Skip to content
  • Tuesday, 29 September 2026
  • 5:27 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Eli Lilly’s Triple Agonist Retatrutide Achieves Remarkable 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes
Laboratory Automation & Robotics

Eli Lilly’s Triple Agonist Retatrutide Achieves Remarkable 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes

Lana Keisha Mar 27, 2026 0

Eli Lilly and Company has announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…

Read More

Posts pagination

1 2
TWiV 1286: Clinical update with Dr. Daniel GriffinEverything Claude Opus 5.5 Actually Ships WithUnderground labs invent new fentanyls faster than forensic labs can keep upGilead Executive Sounds Alarm on Limited Innovation Investment Hindering Access to Advanced Therapies
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must Have
DNA Reveals Four Gentoo Penguin Species and Rewrites Antarctic Evolutionary HistoryTolerance Bio Secures Exclusive Global Rights Outside Japan for Tanabe Pharma Anti-IL-33 Monoclonal Antibody TLB-33 in Landmark $560m DealUnprecedented Genetic Study Reveals Explosive Growth Rates and Origins of Chronic Myeloid Leukemia Years Before DiagnosisAs the dream of the autonomous clinical trial dawns, agent supervision is today’s human job
YOU MAY HAVE MISSED
Molecular & Cell Biology
DNA Reveals Four Gentoo Penguin Species and Rewrites Antarctic Evolutionary History
Angie Faith Sep 29, 2026
Pharmaceutical R&D
Tolerance Bio Secures Exclusive Global Rights Outside Japan for Tanabe Pharma Anti-IL-33 Monoclonal Antibody TLB-33 in Landmark $560m Deal
Teuku Ryan Sep 29, 2026
Stem Cell & Regenerative Medicine
Unprecedented Genetic Study Reveals Explosive Growth Rates and Origins of Chronic Myeloid Leukemia Years Before Diagnosis
Dwi Wanna Sep 29, 2026
Laboratory Automation & Robotics
As the dream of the autonomous clinical trial dawns, agent supervision is today’s human job
Lana Keisha Sep 29, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ